Preventive treatment for Alzheimer's and Parkinson's disease

June 1, 2018, Fraunhofer-Gesellschaft
Semi-automatically generated biochemical networks help researchers map out and recognize connections. Credit: Fraunhofer SCAI

A diagnosis of Alzheimer's disease is devastating for those affected, as there is still no cure for this type of dementia. One hundred years after Alois Alzheimer first described it, we neither have a drug for it, nor do we really understand what causes the severe brain impairment. The EU-based AETIONOMY project could bring about a breakthrough in research: Fraunhofer scientists have teamed up with various partners to identify the early disease mechanisms. They hope to advance research into the causes of this disease using model-based and big data approaches.

More and more people in our aging society suffer from dementia. Some 46 million people are affected worldwide, and it is estimated that this number will rise to around 131 million by 2050. Alzheimer's and Parkinson's are among the most common forms of this disease, and there is still no cure for either one. At best, the available drugs alleviate the symptoms – they do not halt the slow deterioration of the brain. For the pharmaceutical industry, are a highly relevant, yet risky research area. Billions of euros have already been invested in research, but efforts to develop a drug that effectively treats memory loss have remained unsuccessful. Promising substances have regularly failed in the final (Phase III) clinical studies.

Understanding the molecular causes of Alzheimer's

But why do we still not know what causes the disease? "To date, research and classification has been symptom-based. The medical classification system still used for disease diagnosis today dates back to the mid-19th century. New insights – from the field of molecular biology, for instance – are not adequately accounted for," says Prof. Hofmann-Apitius, Head of the Department of Bioinformatics at the Fraunhofer Institute for Algorithms and Scientific Computing SCAI and academic coordinator of the EU-based AETIONOMY project. This research initiative is intended to change that by classifying neurodegenerative diseases based on their rather than their clinical symptoms. Thus, the goal of the project is to systematically catalog the molecular disease mechanisms and identify groups of patients in which these disease mechanisms are active. Then they plan to propose specific treatments for these patient groups.

The major challenge with this approach is that the researchers want to understand the molecular causes of Alzheimer's without being able to go back to the point at which the disease first emerged. After all, the dysfunctional processes that cause neurodegenerative diseases can activate the fatal process that ultimately results in dementia as many as 20 to 30 years before clinical symptoms appear.

Understanding the molecular causes of Alzheimer’s and Parkinson’s disease: The AETIONOMY project is a collaborative undertaking of European scientists from academia and the pharmaceutical industry. Credit: Fraunhofer-Gesellschaft

Identifying new disease mechanisms is a challenge, since the physical processes that trigger a given symptom can differ from one patient to the next. "There is presumably not just one disease mechanism that is identical for all patients, but rather numerous triggers and numerous mechanisms that contribute differently to different individuals' risk of developing the disease," says Hofmann-Apitius. Genetics and epigenetics, for example, play a role, but viral infections in childhood, mental stress and traumatic brain injuries can also increase the risk of a future neurological disease, as several years of relevant epidemiological evidence affirms.

Establishing a mechanism-based classification

Alzheimer's and Parkinson's disease develop at the molecular and cellular level, so this is what AETIONOMY addresses, aiming to establish a mechanism-based taxonomy or classification for the two diseases by the end of 2018. "A reclassification is important if we want to determine which patient needs which drug," says Dr. Phil Scordis from UCB BioPharma, which is jointly leading the project consortium.

The Fraunhofer SCAI researchers are taking a big data approach to the reclassification. "We are using big data to collect all the patient data and publications from clinics, companies and libraries, then linking it to create a knowledge base – which is now available," says Hofmann-Apitius. To this end, the researcher and his team used software they developed themselves: SCAIView enables users to quickly locate aggregated information in large amounts of text. Within minutes, the computer reads millions of publications and translates them into a coherent disease model. The result is a graphical model – a network of causally connected factors. The knowledge base now comprises a network of 3,000 nodes and 35,000 relationships. The collected data can be compared with measurement results from clinical studies and checked for matches, a process specialists call "model validation."

Currently, the researchers are developing an initial taxonomy for classifying patients. There are some indications that it may be possible to identify Alzheimer's and Parkinson's subgroups that are characterized by certain mechanisms. For example, frequent traumatic brain injuries, such as those that occur in American football players, promote the development of Alzheimer's disease. The researchers at Fraunhofer SCAI have already identified 126 disease mechanisms for Alzheimer's disease and 76 for Parkinson's. The results of this research were published in Nature Reviews Drug Discovery. The data was also made available on a publicly accessible web server. "Our new approach is breaking entirely new ground in Alzheimer's research and significantly increasing the chances of finding an effective drug that prevents dementias," concludes Hofmann-Apitius.

A follow-up project that builds on the AETIONOMY research findings is already being planned: it is assumed that previously approved drugs (including, for instance, an asthma drug) that have a neurological side effect in their actual area of use could be used for preventing Alzheimer's disease. Relevant tests will begin soon.

Explore further: Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

Related Stories

Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

May 22, 2018
During the past decade, researchers have identified new ways to detect the earliest biological signs of Alzheimer's disease. These early signs, which are detected by biomarkers, may be present before a person starts to exhibit ...

Scientists discover a variation of the genome predisposing to Alzheimer's disease

May 15, 2018
An article published in Nature Medicine shows that the inheritance of small changes in DNA alters the expression of the PM20D1 gene and is associated with an increased risk of developing Alzheimer's disease.

New approaches to understanding Alzheimer's and Parkinson's disease

July 26, 2016
In a study presented today at the Alzheimer's Association International Conference 2016, researchers at the Douglas Mental Health University Institute have explored how some people may develop the hallmarks of Alzheimer's ...

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 25, 2018
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly ...

New forecast shows 6 million with Alzheimer's disease, cognitive impairment

December 8, 2017
Using new methodology, scientists calculate that approximately 6 million American adults have Alzheimer's disease or mild cognitive impairment, which can sometimes be a precursor to the disease. The estimate, funded by the ...

New brain visualisation of Alzheimer's at different ages holds out hope for faster diagnosis and treatment

September 28, 2017
As Alzheimer's disease is associated with a wide variety of symptoms, usually observed through patients' behaviour and actions, effective and timely treatment has proven elusive. An EU-funded project has contributed towards ...

Recommended for you

Eye conditions provide new lens screening for Alzheimer's disease

August 8, 2018
Alzheimer's disease is difficult to diagnose as well as treat, but researchers now have a promising new screening tool using the window to the brain: the eye.

Potential indicator for the early detection of dementias

August 7, 2018
Researchers at the University of Basel have discovered a factor that could support the early detection of neurodegenerative diseases such as Alzheimer's or Parkinson's. This cytokine is induced by cellular stress reactions ...

pH imbalance in brain cells may contribute to Alzheimer's disease

August 2, 2018
Johns Hopkins Medicine scientists say they have found new evidence in lab-grown mouse brain cells, called astrocytes, that one root of Alzheimer's disease may be a simple imbalance in acid-alkaline—or pH—chemistry inside ...

Newly characterized molecule offers possibilities for novel Alzheimer's treatments

August 2, 2018
Alzheimer's disease is an increasingly prevalent, neurodegenerative condition that erodes memory and other cognitive functions. Treatments for this complex disease have been elusive, although researchers have previously uncovered ...

Alzheimer's drug may stop disease if used before symptoms develop

August 1, 2018
About 50 percent of people who reach the age of 85 will develop Alzheimer's disease. Most will die within about five years of exhibiting the hallmark symptoms of the disease – severe memory loss and a precipitous decline ...

Microfluidic system incorporates neuroinflammation into 'Alzheimer's in a dish' model

July 30, 2018
Building on their development of the first culture system to replicate fully the pathology behind Alzheimer's disease, a Massachusetts General Hospital (MGH) research team has now produced a system that includes neuroinflammation, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.